These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39414416)

  • 1. Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
    Myers AA; Kamat AM
    Eur Urol; 2024 Dec; 86(6):e157. PubMed ID: 39414416
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
    Guske C; Jazayeri SB; Li R
    Eur Urol; 2024 Oct; ():. PubMed ID: 39406614
    [No Abstract]   [Full Text] [Related]  

  • 3. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.
    Tan WS; O'Donnell M; Li R; Kamat AM; Packiam VT
    Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 39492318
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
    Soria F; Rosazza M; Livoti S; Dutto D; Colucci F; Sylvester RJ; Shariat SF; Babjuk M; Palou J; Gontero P
    Eur Urol Focus; 2024 Jul; 10(4):648-653. PubMed ID: 37923633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Psutka SP; Veleber S; Siman J; Holt SK; Jannat S; Wright JL; Lin DW; Gore JL; Schade GR; Annen Z; Greenlee H
    Eur Urol Oncol; 2024 Dec; 7(6):1431-1440. PubMed ID: 38653622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
    Takemura K; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol; 2024 Dec; 86(6):e143-e144. PubMed ID: 38531704
    [No Abstract]   [Full Text] [Related]  

  • 9. Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.
    Manes TJ; DeGenova DT; Taylor BC; Patel JN
    JBJS Essent Surg Tech; 2024; 14(4):. PubMed ID: 39650795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
    Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
    Eur Urol Oncol; 2024 Dec; 7(6):1367-1375. PubMed ID: 38355375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
    Guerrero-Ramos F; Boormans JL; Daneshmand S; Gontero P; Kamat AM; Rouprêt M; Vilaseca A; Shariat SF
    Eur Urol Oncol; 2024 Dec; 7(6):1267-1279. PubMed ID: 38849286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to Eleonora Rosato, Riccardo Lombardo, Vincenzo Li Marzi, Enrico Finazzi Agrò, Cosimo De Nunzio, and Simone Albisinni's Letter to the Editor re: Rano Matta, Refik Saskin, Sarah Neu, et al. Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001.
    Matta R
    Eur Urol Focus; 2024 Jul; 10(4):671. PubMed ID: 37858406
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Marc A. Furrer and Patrick Y. Wuethrich's and Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, and Alberto Briganti's Letters to the Editor re: Jakob Klemm, Michael Rink, Markus Von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
    Klemm J; Koelker M; Shariat SF; Fisch M; Vetterlein MW
    Eur Urol Focus; 2024 Jul; 10(4):674-675. PubMed ID: 37806850
    [No Abstract]   [Full Text] [Related]  

  • 14. Trends and inequalities in BCG immunisation coverage among one-year-olds in Sierra Leone, 2008-2019.
    Osborne A; Wongnaah FG; Bangura C; Ahinkorah BO
    BMC Public Health; 2024 Nov; 24(1):3342. PubMed ID: 39616317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
    Li R; Hensley PJ; Gupta S; Al-Ahmadie H; Babjuk M; Black PC; Brausi M; Bree KK; Fernández MI; Guo CC; Horowitz A; Lamm DL; Lerner SP; Lotan Y; Mariappan P; McConkey D; Mertens LS; Mir C; Ross JS; O'Donnell M; Palou J; Pohar K; Steinberg G; Soloway M; Spiess PE; Svatek RS; Tan WS; Taoka R; Buckley R; Kamat AM
    Eur Urol; 2024 Dec; 86(6):516-527. PubMed ID: 39183090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Kelly JD;
    Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau.
    Berendsen MLT; Bles P; de Bree LCJ; Jensen KJ; Jensen CC; Wejse C; Mendes DV; Netea MG; Benn CS
    Vaccine; 2024 Dec; 42(26):126439. PubMed ID: 39423450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer.
    Peng Y; Song Y; Qin C; Du Y; Xu T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2425529. PubMed ID: 39539079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective trial of a uniform protocol for managing infants with neurogenic bladder.
    Macedo A; Campelo TR; Aragon RG; Macedo EL; Garrone G; Ottoni SL; Leal da Cruz M
    J Pediatr Urol; 2024 Dec; 20(6):1125-1130. PubMed ID: 39232867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of standardized patient simulation with BCG vaccination on nursing students' skills, knowledge and satisfaction, and self-confidence: A randomized controlled study.
    Unal E; Ozdemir A; Aydın MO; Alper Z
    Nurse Educ Pract; 2024 Nov; 81():104159. PubMed ID: 39447444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.